Michael Ulz
Stock Analyst
(3.41)
# 304
Out of 4,648 analysts
109
Total ratings
54.55%
Success rate
3.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLN Silence Therapeutics | Reiterates: Overweight | $49 | $17.83 | +174.82% | 10 | Oct 8, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Overweight | $105 | $63.14 | +66.30% | 2 | Sep 12, 2024 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $48 → $52 | $28.78 | +80.68% | 2 | Aug 14, 2024 | |
| YMAB Y-mAbs Therapeutics | Maintains: Underweight | $12 → $11 | $14.87 | -26.03% | 6 | Aug 13, 2024 | |
| THRD Third Harmonic Bio | Upgrades: Overweight | $12 → $20 | $12.11 | +65.22% | 4 | Aug 9, 2024 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $110 → $115 | $91.88 | +25.16% | 9 | Jul 12, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $250 → $255 | $269.95 | -5.54% | 8 | Jul 12, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $53 → $57 | $40.45 | +40.91% | 3 | Jun 18, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Equal-Weight | $36 → $27 | $20.06 | +34.60% | 4 | May 13, 2024 | |
| KYTX Kyverna Therapeutics | Initiates: Overweight | $40 | $5.16 | +675.19% | 1 | Mar 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $2.76 | +153.62% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $2.56 | +603.13% | 1 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $1 → $0.5 | $0.89 | -43.63% | 4 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $25 | $4.00 | +525.00% | 5 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $48 | $38.44 | +24.87% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $33 | $32.05 | +2.96% | 3 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $9.48 | +184.81% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $4 | $0.93 | +328.72% | 4 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $23 | $11.44 | +101.05% | 3 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $2.24 | +792.86% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $16.82 | +167.54% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $1.44 | +594.44% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $8 | $1.25 | +540.00% | 5 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $1.34 | +123.88% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $9.37 | +220.17% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $30 | $15.69 | +91.20% | 3 | Mar 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $8.97 | +401.67% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $20 | $1.84 | +986.96% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $51.06 | +56.68% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $11.33 | +32.39% | 3 | Jul 12, 2017 |
Silence Therapeutics
Oct 8, 2024
Reiterates: Overweight
Price Target: $49
Current: $17.83
Upside: +174.82%
Viking Therapeutics
Sep 12, 2024
Reiterates: Overweight
Price Target: $105
Current: $63.14
Upside: +66.30%
Dyne Therapeutics
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $28.78
Upside: +80.68%
Y-mAbs Therapeutics
Aug 13, 2024
Maintains: Underweight
Price Target: $12 → $11
Current: $14.87
Upside: -26.03%
Third Harmonic Bio
Aug 9, 2024
Upgrades: Overweight
Price Target: $12 → $20
Current: $12.11
Upside: +65.22%
Blueprint Medicines
Jul 12, 2024
Maintains: Equal-Weight
Price Target: $110 → $115
Current: $91.88
Upside: +25.16%
Alnylam Pharmaceuticals
Jul 12, 2024
Maintains: Equal-Weight
Price Target: $250 → $255
Current: $269.95
Upside: -5.54%
Mirum Pharmaceuticals
Jun 18, 2024
Maintains: Overweight
Price Target: $53 → $57
Current: $40.45
Upside: +40.91%
Arrowhead Pharmaceuticals
May 13, 2024
Maintains: Equal-Weight
Price Target: $36 → $27
Current: $20.06
Upside: +34.60%
Kyverna Therapeutics
Mar 4, 2024
Initiates: Overweight
Price Target: $40
Current: $5.16
Upside: +675.19%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $2.76
Upside: +153.62%
Feb 27, 2024
Initiates: Overweight
Price Target: $18
Current: $2.56
Upside: +603.13%
Jan 5, 2024
Downgrades: Underweight
Price Target: $1 → $0.5
Current: $0.89
Upside: -43.63%
Nov 29, 2023
Maintains: Overweight
Price Target: $28 → $25
Current: $4.00
Upside: +525.00%
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $45 → $48
Current: $38.44
Upside: +24.87%
Oct 11, 2023
Maintains: Overweight
Price Target: $70 → $33
Current: $32.05
Upside: +2.96%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $9.48
Upside: +184.81%
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $5 → $4
Current: $0.93
Upside: +328.72%
May 23, 2023
Maintains: Outperform
Price Target: $20 → $23
Current: $11.44
Upside: +101.05%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $2.24
Upside: +792.86%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $16.82
Upside: +167.54%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $1.44
Upside: +594.44%
Jan 27, 2023
Maintains: Equal-Weight
Price Target: $6 → $8
Current: $1.25
Upside: +540.00%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $1.34
Upside: +123.88%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $9.37
Upside: +220.17%
Mar 30, 2022
Maintains: Equal-Weight
Price Target: $25 → $30
Current: $15.69
Upside: +91.20%
Oct 8, 2020
Initiates: Outperform
Price Target: $45
Current: $8.97
Upside: +401.67%
May 28, 2020
Maintains: Outperform
Price Target: $12 → $20
Current: $1.84
Upside: +986.96%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $51.06
Upside: +56.68%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $11.33
Upside: +32.39%